2
(37°C) was then reinstated for 60 min. Hearts were divided into 2 groups according to the perfusion protocol shown in Fig. 1A: 1. Control group. Fifteen hearts were not subjected to any episode of hypothermic perfusion.
2. TP group. Twelve hearts experienced 20 min equilibration at 37°C, then 3 cycles of 2 min hypothermic perfusion at 26°C interspersed with 6 min normothermic perfusion prior to ischaemia.
Samples of effluent perfusate from all hearts subjected to ischaemia and reperfusion were collected at the times indicated for determination of lactate dehydrogenase (LDH) activity. Eight and six additional hearts of each group were freeze-clamped following 44 min preischaemia and 15 min reperfusion respectively. The hearts were ground under liquid nitrogen and stored at -80 o C for later analysis. Hearts harvested at the preischaemia were used for analysis of cyclic AMP (cAMP) concentration, PKA activity and Akt and GSK3 phosphorylation. Hearts freeze-clamped after 15 min reperfusion were used for analysis of Akt and GSK3 phosphorylation.
Experimental Series 2
After 51 min preischaemia, global normothermic ischaemia was induced for 30 min followed by 60 min normothermic reperfusion. Hearts were divided into 6 groups (6-10 hearts in each)
according to the pre-ischaemic perfusion protocol shown in Fig. 1B: 1. Control group. Hearts were perfused with KH at normothermia prior to ischaemia.
2. TP hearts experienced a 25 min equilibration period at normothermia followed by 3 episodes of 2 min hypothermic perfusion (26°C) interspersed with 6 min normothermic perfusion after the first and second episode of hypothermia and 8 min after the third period of hypothermia prior to ischaemia.
3. Control Sotalol (CS) group. Hearts were subject to a 20 min equilibration period before 26 min normothermic perfusion with KH containing 10 µM of the non-selective β-adrenergic blocker sotalol (Sigma). Sotalol was washed out for 5 min prior to ischaemia. 
Experimental Series 3
After 32 min preischaemia, global normothermic ischaemia was induced for 30 min followed by 60 min normothermic reperfusion. Hearts were divided into four groups (7-9 hearts in each)
according to the pre-ischaemic perfusion protocol shown in Fig. 1C: 1. Control group. Hearts were perfused with KH at normothermia for 32 min prior to ischaemia.
2. Isoproterenol group. After 20 min equilibration period, hearts were perfused with KH containing 0.2 µM non-selective β-adrenergic agonist isoproterenol (Sigma) for 2 min followed by 10 min washout.
3. Adenosine group. After 22 min equilibration period, hearts were perfused with KH containing 30 µM of the PKC activator adenosine (Sigma) followed by 5 min washout.
4. Group of the consecutive isoproterenol/adenosine treatment. Hearts were perfused with isoproterenol followed by perfusion with adenosine and 5 min washout following 20 min equilibration period.
Eight additional non-ischaemic hearts of each group were freeze-clamped following 27 min KH perfusion (group 1) or immediately after isoproterenol (group 2) or adenosine treatment (groups 3 and 4), ground under liquid nitrogen and stored at -80 o C for later analysis of PKC activity. Eight more hearts of each group were freeze-clamped and ground following the corresponding preischaemic protocol (including 5 min washout) and used for measuring glycogen content in myocardium whilst 7-10 other hearts of each group were used to isolate mitochondria after 30 min global ischaemia for measurement of MPTP opening. Some mitochondria were stored at -80 o C for future analysis of protein carbonylation.
Experimental Series 4
After 37 min preischaemia, global normothermic ischaemia was induced for 30 min followed by 60 min normothermic reperfusion. Hearts were divided into eight groups (5-8 heats each)
according to the pre-ischaemic perfusion protocol ( Fig. 1C ):
1. Control group. Eight hearts were perfused with KH at normothermia for 37 min prior to ischaemia.
2. Isoproterenol group. After 25 min equilibration period, 5 hearts were perfused with KH containing 0.2 µM isoproterenol for 2 min followed by 10 min washout.
3. Adenosine group. After 27 min equilibration period, 5 hearts were perfused with KH containing 30 µM adenosine followed by 5 min washout.
4. Group of the consecutive Isoproterenol/Adenosine treatment. Five hearts were perfused with isoproterenol followed by perfusion with adenosine and 5 min washout following 25 min equilibration period.
5. Isoproterenol + Chelerythrine group. Isoproterenol treatment, performed as for group 2, was combined with 17 min perfusion with the PKC inhibitor chelerythrine (10 µM) on 5
hearts. Perfusion with chelerythrine was started 5 min before and completed at the end of the preischaemic protocol. We have previously shown that chelerythrine at this concentration has no effect on heart function at the preischaemia and heart recovery during reperfusion 2 .
5 6. Adenosine + Chelerythrine group. Adenosine treatment, performed like in group 3, was combined with 17 min perfusion with chelerythrine on 5 hearts. Perfusion with chelerythrine was started 7 min before and completed 5 min after the adenosine treatment.
7. Group of the consecutive Isoproternol/Adenosine treatment + Chelerythrine. The consecutive isoproterenol and adenosine treatment, performed like in group 4, was combined with 17 min perfusion with chelerythrine on 7 hearts. Perfusion with chelerythrine was started 5 min before the isoproterenol perfusion and completed at the end of the preischaemic protocol.
8. Group of the mixed Isoproterenol/Adenosine treatment. Six hearts of this group were perfused with adenosine for 5 min. After 1.5 min adenosine perfusion, isoproterenol was delivered to the heart together with adenosine for 2 min followed by further 1.5 min perfusion with adenosine alone and 5 min washout. Thus, hearts received the same doses of isoproterenol and adenosine yet perfusion with isoproterenol did not precede but was mixed with adenosine perfusion.
Assays
Cyclic AMP concentration, PKC and PKA activity, glycogen content and Akt and GSK3 phosphorylation were determined in the hearts following freeze-clamping, whilst protein carbonylation was determined in frozen mitochondria as shown in the Experimental Protocol.
Cyclic AMP concentration
Cyclic AMP concentration was determined using a direct enzyme immunoassay kit (Sigma).
Samples of the frozen hearts were suspended in 0.1 M HCl at room temperature and centrifuged at 600 x g for 10 min. Protein concentration in the supernatant was determined using a bicinchoninic acid-based (BCA) protein assay (Pierce) and adjusted to 3 mg/ml before the spectrofluorimetric assay of cyclic AMP according to the manufacturer's instructions.
PKA and PKC activity
For assay of PKA activity, samples of the frozen and ground hearts were vortex-mixed into buffer (pH 7.4, 4°C) containing (mM) 25 Tris-HCl, 0.5 EDTA, 0.5 EGTA, 10 β-mercaptoethanol (Sigma), and complete protease inhibitor cocktail (Roche Diagnostics) and centrifuged at 14000 x g for 5 min. For assay of PKC activity samples of the frozen and ground hearts were vortex-mixed into buffer (pH 7.4, 4°C) containing (mM) 25 Tris-HCl, 0.5 EDTA, 0.5 EGTA, 10 β-mercaptoethanol, 0.05% Triton® X-100 (Sigma) and complete protease inhibitor cocktail (Roche Diagnostics) and centrifuged at 10000 x g for 5 min. Protein concentration in the supernatant was determined using the Biuret assay and adjusted to 4 mg/ml. PKA and PKC activity was measured using non-radioactive 
Western blots (Phosphorylation of Akt and GSK3 and protein carbonylation)
The phosphorylation of Akt and GSK3 was determined by a method based on that of Hausenloy et al. 2, 3 Briefly 100 mg of frozen tissue were suspended in 0.5 ml of buffer (4°C) containing (mM) 300 sucrose, 10 Tris-HCl, 1 EGTA, 2 sodium pyrophosphate, 2 sodium fluoride, 2 β-glycerophosphate, complete protease inhibitor cocktail (Roche Diagnostics) and phosphatase inhibitor cocktail 1 (Sigma). The suspension was sonicated three times in 5 s bursts and centrifuged at 10,000 x g for 10 min to separate cytosol (supernatant) and particulate fractions (pellet). Cytosolic samples were dissolved in SDS-PAGE sample buffer, boiled at 100°C for 10 min and normalised to 3 mg/ml using BCA protein assay. Proteins were separated by 10% SDS-PAGE and revealed using
Western blotting with antibodies (diluted 1:500) against total Akt and GSK3β, and phosphorylated Akt and GSK3α/β (Cell Signaling Technology). Each blot contained samples from control and TP hearts and separate gels were run for total protein (45 µg per lane) and phosphoproteins (75 µg per lane). The ratio of the band intensity for phosphoprotein to total protein was used as a measure of phosphorylation state.
For determination of protein carbonyls, frozen mitochondria samples were thawed and protein concentration was adjusted twice to a final concentration of 4 mg/ml using BCA protein assay.
Protein carbonyls were determined following derivatization with dinitrophenylhydrazine (Chemicon International, Chandlers Ford, UK) exactly as previously described 4 . Derivatized proteins (10 µg)
were separated by 10% SDS-PAGE and subjected to Western blotting with antidinitrophenyl antibodies (Sigma, diluted 1 : 1000). Samples of the four groups of hearts of the Experimental Series 3 and non-ischaemic control hearts were included on the same blot and consistent protein loading and transfer, essential for accurate comparison between groups, was confirmed by Coomassie Blue staining (Supplementary Figure) . Samples of non-derivatized proteins were run in parallel to correct for non-specific antibody binding.
Western blots were developed using anti-rabbit Ig horseradish peroxidase secondary antibody with ECL/ECL+ detection (Amersham Biosciences UK Ltd). All quantification of blots was performed using an AlphaInotech ChemiImager 4400 with AlphaEase v5.5 software to analyse band intensity, followed by background subtraction.
Glycogen content
Glycogen content was assessed by measuring the glucose released from glycogen breakdown by amyloglucosidase based on the method described by 
Mitochondrial isolation
Ventricles were rapidly cut away, and homogenized with a Polytron homogenizer at setting 3 for 5 s in 3 ml of ice-cold sucrose buffer (mmol/L: sucrose 300, Tris-HCl 10, EGTA 2; pH 7.4). The homogenate was rapidly diluted to 40 ml with the sucrose buffer containing 5 mg/ml bovine serum albumin (BSA), centrifuged at 2000 x g for 90 s to remove cell debris. Supernatant was centrifuged at 12000 x g for 5 min. The resulting pellet containing mitochondria was washed once in 40 ml sucrose buffer with 5 mg/ml BSA, centrifuged at 12000 x g for 5 min and resuspended in 200 µl of the same buffer. Some of these freshly prepared mitochondria were used for the MPTP opening assay and remaining mitochondria were frozen in liquid nitrogen and stored at -80ºC for further analysis of protein carbonyls.
Mitochondrial permeability transition pore (MPTP) opening in isolated mitochondria.
The opening of the MPTP in de-energised mitochondria at 30°C was determined as previously 
